['spondyloarthritis']
['ixekizumab', 'placebo']

        Inclusion Criteria:

          -  Are ambulatory.

          -  Have an established diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with
             sacroiliitis defined radiographically according to the modified New York criteria.

          -  Participants have a history of back pain ≥3 months with age at onset <45 years.

          -  Have had prior treatment with at least 1 and not more than 2 TNF inhibitors.

          -  Must have had an inadequate response to 2 or more NSAIDs at the therapeutic dose range
             for a total duration of at least 4 weeks OR have a history of intolerance to NSAIDs.

          -  Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.

        Exclusion Criteria:

          -  Have total ankylosis of the spine.

          -  Have never taken a TNF inhibitor medication or have taken more than 2.

          -  Have recently received a live vaccine within 12 weeks or have had a vaccination with
             Bacillus Calmette-Guerin (BCG) within the past year.

          -  Have an ongoing or serious infection within the last 12 weeks or evidence of active
             tuberculosis.

          -  Have a compromised immune system.

          -  Have any other serious and/or uncontrolled diseases.

          -  Have either a current diagnosis or a recent history of malignant disease.

          -  Have had major surgery within 8 weeks of baseline, or will require surgery during the
             study.

          -  Are pregnant or breastfeeding.
      